Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Regen BioPharma Inc. (OTCBB:RGBP)Chairman Discusses The Rationale For Pursuing Autoimmune Indications By Activating The Nuclear Receptor NR2F6

|About: Regen Biopharma, Inc. (RGBP)

Summary

NR2F6 is the Key to the Future.

Focus Small Molecule.

Focusing on Cancer & Auto Immune (Lupus).

Potential Buyout Target.

Key Partners Eli Lily & Chem Div.

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

Summary

NR2F6 is the Key to the Future

Focus Small Molecule

Focusing on Cancer & Auto Immune (Lupus)

Potential Buyout Target

PR Newswire

SAN DIEGO, November 16, 2017

There are currently about 9 companies working on activating immune checkpoints, but Regen appears to be the sole company known to be working on utilizing small molecules to activate immune checkpoints (How immuno-oncology targets are spawning new therapies for inflammation). 

18 months ago, Regen BioPharma Inc. (OTCQB:

RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that

inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been

identified as a potentially very important immune cell inhibitor (an immune

checkpoint) and cancer stem cell differentiator. Regen BioPharma believes

that by inhibiting the NR2F6 nuclear receptor, one can unleash the

cancer-killing potential of a patient's own immune system. Regen is also

engaged in the identification of small molecules which activate the NR2F6

nuclear receptor that can be utilized to develop small molecule therapies for

autoimmune disorders "The rationale for activating the NR2F6 nuclear

receptor (also known as a checkpoint) is straightforward - if inhibiting the

checkpoint activates the immune system and thus helps kill cancer cells, then

conversely, activating the checkpoint should suppress the immune system and

thus be useful in diseases where the immune system is over-activated, such as

rheumatoid arthritis, lupus, colitis and many other autoimmune diseases,"

says David Koos, Ph.D., Chairman and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. 

Other biotechnology companies arefocused on antibodies that have much more cumbersome delivery methods (hospitalstays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection."

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

About Regen BioPharma Inc.:  

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: OTCQB:RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com

Recent News:

Regen BioPharma, Inc. Announces Former Eli Lilly Executive And Current CVS Board Member Will Lead Newly Formed Business Advisory Board

Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (NYSEARCA:BAB)

Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

Structures with &Without Small Molecules to be Determined

Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6 

Regen BioPharma, Inc. Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases

https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5050212-rgbp-nr2f6-nuclear-receptor-identified-demonstrates-important-immune-cell-inhibitor-and …

Key Partners – Eli Lily & Company – Chem Div

We believe Regen BioPharma is a Long Play, with a great upside with all the items in its Pipeline. Very possibly a Buy Out Target.

RGBP also has Short Term Gain Potential that has recently moved up near 106%. Moving from $.036 on 11/9/17 to Closing today @ $0.074. Increased liquidity has been present as well.

If you have any questions concerning (OTCQB:RGBP) or have a need for more information, please feel free to contact me. 

Robert E. Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

robkreh@gmail.com 

(OTCQB:RGBP) Disclaimer:

You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker()/Broker Dealer() with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.